MoonLake Immunotherapeutics
MLTX15.510USD
+0.740+5.01%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
988.06MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MoonLake Immunotherapeutics Unternehmen
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics Informationen
BörsenkürzelMLTX
Name des UnternehmensMoonLake Immunotherapeutics
IPO-datumOct 20, 2020
CEOSantos Da Silva (Jorge)
Anzahl der mitarbeiter100
WertpapierartOrdinary Share
GeschäftsjahresendeOct 20
AddresseDorfstrasse 29
StadtZUG
BörseNASDAQ OMX - NASDAQ BASIC
LandSwitzerland
Postleitzahl6300
Telefon41415108022
Websitehttps://moonlaketx.com/
BörsenkürzelMLTX
IPO-datumOct 20, 2020
CEOSantos Da Silva (Jorge)
Führungskräfte von MoonLake Immunotherapeutics
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.96M
-167519.00%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.28M
+354296.00%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.96M
-167519.00%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.28M
+354296.00%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
27.88%
Deep Track Capital LP
6.51%
Santos da Silva (Jorge)
4.34%
Reich (Kristian)
4.18%
Avoro Capital Advisors LLC
2.82%
Andere
54.27%
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
27.88%
Deep Track Capital LP
6.51%
Santos da Silva (Jorge)
4.34%
Reich (Kristian)
4.18%
Avoro Capital Advisors LLC
2.82%
Andere
54.27%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
47.83%
Individual Investor
10.56%
Investment Advisor
6.71%
Investment Advisor/Hedge Fund
5.77%
Research Firm
1.10%
Venture Capital
0.49%
Sovereign Wealth Fund
0.33%
Bank and Trust
0.11%
Pension Fund
0.04%
Andere
27.06%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
347
43.70M
61.69%
-21.61M
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BVF Partners L.P.
19.75M
27.88%
--
--
Nov 06, 2025
Deep Track Capital LP
4.61M
6.51%
+4.61M
--
Nov 05, 2025
Santos da Silva (Jorge)
3.07M
4.34%
-3.68K
-0.12%
Dec 19, 2025
Reich (Kristian)
2.96M
4.18%
-167.52K
-5.35%
Dec 19, 2025
Avoro Capital Advisors LLC
2.00M
2.82%
-2.15M
-51.81%
Sep 30, 2025
Cormorant Asset Management, LP
1.99M
2.81%
-6.50M
-76.52%
Sep 30, 2025
Balyasny Asset Management LP
1.70M
2.4%
+1.28M
+301.55%
Sep 30, 2025
Adage Capital Management, L.P.
1.50M
2.12%
+1.50M
--
Sep 30, 2025
Bodenstedt (Matthias)
922.01K
1.3%
+294.47K
+46.93%
Dec 19, 2025
Schonfeld Strategic Advisors LLC
965.40K
1.36%
+965.40K
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.22%
Virtus LifeSci Biotech Clinical Trials ETF
0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
Strive Small-Cap ETF
0.02%
Nuveen ESG Small-Cap ETF
0.02%
iShares Morningstar Small-Cap ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Mehr Anzeigen
ALPS Medical Breakthroughs ETF
Anteil0.27%
Global X Guru Index ETF
Anteil0.22%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
Anteil0.02%
Strive Small-Cap ETF
Anteil0.02%
Nuveen ESG Small-Cap ETF
Anteil0.02%
iShares Morningstar Small-Cap ETF
Anteil0.01%
John Hancock Multifactor Small Cap ETF
Anteil0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
Anteil0.01%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
